Tourmaline Bio

Tourmaline Bio

Developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Learn more

Launch date
Employees
Market cap
CAD674m
Enterprise valuation
CAD279m (Public information from Sep 2024)
New York City New York (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD20222023202420252026
Revenues---10.0m12.0m
% growth----20 %
EBITDA(19.7m)(45.4m)---
Profit(19.7m)(42.1m)(78.1m)(99.0m)(124m)
% profit margin---(990 %)(1035 %)
EV / revenue----1.4x10.0x
EV / EBITDA--11.7x---
R&D budget17.5m32.4m---
  • Edit

Recent News about Tourmaline Bio

Edit
More about Tourmaline Bioinfo icon
Edit

Tourmaline Bio is a biotechnology company focused on developing transformative medicines aimed at dramatically improving the lives of patients with life-altering immune diseases. The company operates in the biopharmaceutical market, targeting rare and significant unmet medical needs. Tourmaline Bio serves patients suffering from severe immune disorders, working closely with healthcare providers and research institutions. Their business model revolves around the research, development, and commercialization of innovative therapies. Revenue is generated through the successful development and approval of these therapies, followed by their commercialization either directly or through partnerships with larger pharmaceutical companies.

Keywords: biotechnology, immune diseases, transformative medicines, rare diseases, drug development, biopharmaceutical, healthcare, innovation, commercialization, research.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Tourmaline Bio

Edit
Talaris Therapeutics
ACQUISITION by Tourmaline Bio Jun 2023